PortfoliosLab logoPortfoliosLab logo
FHLC vs. IDNA
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

FHLC vs. IDNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Fidelity MSCI Health Care Index ETF (FHLC) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, FHLC achieves a -3.90% return, which is significantly lower than IDNA's 10.31% return.


FHLC

1D
0.82%
1M
1.50%
YTD
-3.90%
6M
-4.11%
1Y
14.43%
3Y*
6.14%
5Y*
4.50%
10Y*
9.14%

IDNA

1D
0.73%
1M
-2.56%
YTD
10.31%
6M
8.52%
1Y
40.87%
3Y*
6.74%
5Y*
-8.42%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

FHLC vs. IDNA - Yearly Performance Comparison


2026 (YTD)2025202420232022202120202019
FHLC
Fidelity MSCI Health Care Index ETF
-3.90%15.42%2.48%2.58%-5.55%20.39%18.13%13.43%
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund
10.31%17.26%-0.72%-7.63%-42.28%-3.98%54.30%20.83%

Correlation

The correlation between FHLC and IDNA is 0.68, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.68

Correlation (3Y)
Calculated over the trailing 3-year period

0.63

Correlation (5Y)
Calculated over the trailing 5-year period

0.65

Correlation (All Time)
Calculated using the full available price history since Jun 14, 2019

0.67

The correlation between FHLC and IDNA has been stable across timeframes, ranging from 0.63 to 0.68 - a consistent structural relationship.

FHLC vs. IDNA - Sectors Allocation Comparison


Sectors
FHLC
IDNA

Healthcare

99.6%
97.8%

Financial Services

0.1%

-

Technology

0.0%

-

Industrials

0.0%
0.4%

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

-

Real Estate

-

-

Utilities

-

-

Healthcare

FHLC
99.6%
IDNA
97.8%

Financial Services

FHLC
0.1%
IDNA

-

Technology

FHLC
0.0%
IDNA

-

Industrials

FHLC
0.0%
IDNA
0.4%

Basic Materials

FHLC

-

IDNA

-

Communication Services

FHLC

-

IDNA

-

Consumer Cyclical

FHLC

-

IDNA

-

Consumer Defensive

FHLC

-

IDNA

-

Energy

FHLC

-

IDNA

-

Real Estate

FHLC

-

IDNA

-

Utilities

FHLC

-

IDNA

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

FHLC vs. IDNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

FHLC
FHLC Risk / Return Rank: 2727
Overall Rank
FHLC Sharpe Ratio Rank: 2727
Sharpe Ratio Rank
FHLC Sortino Ratio Rank: 2929
Sortino Ratio Rank
FHLC Omega Ratio Rank: 2626
Omega Ratio Rank
FHLC Calmar Ratio Rank: 2828
Calmar Ratio Rank
FHLC Martin Ratio Rank: 2626
Martin Ratio Rank

IDNA
IDNA Risk / Return Rank: 5555
Overall Rank
IDNA Sharpe Ratio Rank: 4848
Sharpe Ratio Rank
IDNA Sortino Ratio Rank: 4949
Sortino Ratio Rank
IDNA Omega Ratio Rank: 4242
Omega Ratio Rank
IDNA Calmar Ratio Rank: 7676
Calmar Ratio Rank
IDNA Martin Ratio Rank: 6161
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

FHLC vs. IDNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Fidelity MSCI Health Care Index ETF (FHLC) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


FHLCIDNADifference
Sharpe ratioReturn per unit of total volatility

-0.67

Sortino ratioReturn per unit of downside risk

-0.86

Omega ratioGain probability vs. loss probability

1.18

1.27

-0.09

Calmar ratioReturn relative to maximum drawdown

1.40

3.85

-2.45

Martin ratioReturn relative to average drawdown

3.52

10.98

-7.46

FHLC vs. IDNA - Sharpe Ratio Comparison

The current FHLC Sharpe Ratio is 1.01, which is lower than the IDNA Sharpe Ratio of 1.68. The chart below compares the historical Sharpe Ratios of FHLC and IDNA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


FHLCIDNADifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.01

1.68

-0.67

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.30

-0.30

+0.60

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.55

Sharpe Ratio (All Time)

Calculated using the full available price history

0.61

0.10

+0.51

Drawdowns

FHLC vs. IDNA - Drawdown Comparison

The maximum FHLC drawdown since its inception was -28.76%, smaller than the maximum IDNA drawdown of -68.26%. Use the drawdown chart below to compare losses from any high point for FHLC and IDNA.


Loading charts...

Drawdown Indicators


FHLCIDNADifference

Max Drawdown

Largest peak-to-trough decline

-28.76%

-68.26%

+39.50%

Max Drawdown (1Y)

Largest decline over 1 year

-10.38%

-10.66%

+0.28%

Max Drawdown (3Y)

Largest decline over 3 years

-16.87%

-29.73%

+12.86%

Max Drawdown (5Y)

Largest decline over 5 years

-17.73%

-68.26%

+50.53%

Max Drawdown (10Y)

Largest decline over 10 years

-28.76%

Current Drawdown

Current decline from peak

-6.96%

-45.61%

+38.65%

Average Drawdown

Average peak-to-trough decline

-5.19%

-36.24%

+31.05%

Ulcer Index

Depth and duration of drawdowns from previous peaks

4.11%

3.73%

+0.38%

Volatility

FHLC vs. IDNA - Volatility Comparison

The current volatility for Fidelity MSCI Health Care Index ETF (FHLC) is 4.05%, while iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) has a volatility of 7.18%. This indicates that FHLC experiences smaller price fluctuations and is considered to be less risky than IDNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


FHLCIDNADifference

Volatility (1M)

Calculated over the trailing 1-month period

4.05%

7.18%

-3.13%

Volatility (6M)

Calculated over the trailing 6-month period

10.11%

17.98%

-7.87%

Volatility (1Y)

Calculated over the trailing 1-year period

14.33%

24.48%

-10.15%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

14.97%

28.42%

-13.45%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

16.81%

29.53%

-12.72%

FHLC vs. IDNA - Expense Ratio Comparison

FHLC has a 0.08% expense ratio, which is lower than IDNA's 0.47% expense ratio.


Dividends

FHLC vs. IDNA - Dividend Comparison

FHLC's dividend yield for the trailing twelve months is around 1.43%, more than IDNA's 1.07% yield.


PositionTTM20252024202320222021202020192018201720162015
FHLC
Fidelity MSCI Health Care Index ETF
1.43%1.40%1.51%1.40%1.30%1.16%1.45%1.18%1.38%1.38%1.40%2.07%
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund
1.07%1.18%0.98%1.04%0.54%0.70%0.26%0.80%0.00%0.00%0.00%0.00%

Frequently Asked Questions


FHLC and IDNA have a correlation of 0.68, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

IDNA has higher volatility (7.18%) compared to FHLC (4.05%). In terms of maximum drawdown, FHLC dropped -28.76% vs IDNA's -68.26%.

On 5-year performance, FHLC leads with 4.50% vs -8.42% for IDNA. On fees, FHLC is cheaper at 0.08% per year. On volatility, FHLC has been the lower-risk option at 4.05%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 5-year period, FHLC has performed better with a 4.50% return vs -8.42%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

FHLC is cheaper with a 0.08% expense ratio, compared with 0.47% for IDNA.

FHLC has the higher dividend yield at 1.43%, compared with 1.07% for IDNA.

FHLC tracks MSCI USA IMI Health Care Index, while IDNA tracks NYSE FactSet Global Genomics and Immuno Biopharma Index. They also come from different issuers: Fidelity and iShares. Their fees differ too: 0.08% for FHLC and 0.47% for IDNA.

IDNA currently has the higher Sharpe Ratio (1.68 vs 1.01), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for FHLC and IDNA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer